<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366128</url>
  </required_header>
  <id_info>
    <org_study_id>XHLSG-NK-1902</org_study_id>
    <nct_id>NCT04366128</nct_id>
  </id_info>
  <brief_title>Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL</brief_title>
  <official_title>Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE Natural Killer /T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rong Tao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of camrelizumab, apatinib,&#xD;
      pegaspargase (CAPA) and as an intruction immunotherapy with radiotherapy as first-line&#xD;
      treatment in patients with de novo stage IE/IIE extranodal natural killer/T-cell lymphoma,&#xD;
      nasal type.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extranodal natural killer/T-cell lymphoma (ENKTCL), nasal type, is a rare subtype of&#xD;
      non-Hodgkin lymphoma (NHL) with relatively high incidence in China. Radiotherapy alone for&#xD;
      stage IE/IIE diseases has good response rate but with high relapse rates, ranging from&#xD;
      20-50%. The combination of chemotherapy and radiotherapy improved the long-term survival for&#xD;
      patients with stage IE/IIE diseases. But the optimal treatment schedule has not been&#xD;
      established. This study is designed with four cycles CAPA induction immunotherapy, followed&#xD;
      by 50-56Gy radiotherapy as an approach for stage IE/IIE ENKTCL. The efficacy and safety of&#xD;
      this treatment will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Camrelizumab, apatinib and pegaspargase</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Camrelizumab, apatinib and pegaspargase indution immunotherapy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete response at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of patients with complete response (CR) at week 24 evaluate by Lugano 2014 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of overall response rate at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of patients with complete response and partial response (ORR) at week 24 evaluate by Lugano 2014 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival at 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>overall survival rate (OS) of patients at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of progression free survival at 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>progression free survival rate (PFS) of patients at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent of adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>adverse events graded by NCI CTCAE Ver4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type</condition>
  <arm_group>
    <arm_group_label>CAPA indution immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAPA regimen, repeat every 3 week for 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAPA indution immunotherapy</intervention_name>
    <description>Camelirumab 200mg Intravenous injection on day 1.&#xD;
Apatinib 250mg taken orally once daily.&#xD;
Pegaspargase 2000U/m2 Intramuscular injection on day 1.</description>
    <arm_group_label>CAPA indution immunotherapy</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who meet the WHO 2016 diagnostic criteria for NK/T-cell lymphoma by biopsy&#xD;
             histopathology, immunohistochemistry and EBER.&#xD;
&#xD;
          -  The primary site is in the nasal cavity or upper gastrointestinal tract. The de novo&#xD;
             diagnosed patient has at least one objective and evaluable lesion.&#xD;
&#xD;
          -  Stage IE / IIE disease according to Lugano 2014 lymphoma staging system.&#xD;
&#xD;
          -  ECOG score 0-3.&#xD;
&#xD;
          -  The laboratory examination within 1 week before entering the group meets the following&#xD;
             conditions:&#xD;
&#xD;
               1. Blood routine test: neutrophil count≥1.0 × 10^9/L, Hemoglobin≥80g/L, Platelet≥50&#xD;
                  × 10^9/L.&#xD;
&#xD;
               2. Coagulation routine: plasma fibrinogen ≥ 1.0g / L.&#xD;
&#xD;
               3. Liver function: Alanine aminotransferase, aspartate aminotransferase and total&#xD;
                  bilirubin ≤ 2 times the upper limit of normal value.&#xD;
&#xD;
               4. Renal function: Creatinine is normal.&#xD;
&#xD;
               5. Refers to oxygen saturation&gt; 93%.&#xD;
&#xD;
               6. Cardiac function: Left ventricular ejection fraction ≥50%, electrocardiogram does&#xD;
                  not suggest any acute myocardial infarction, arrhythmia or atrioventricular block&#xD;
                  above 1 degree&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Voluntarily follow the research protocol, follow-up plan, laboratory and auxiliary&#xD;
             examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  accompanied with HCV or HIV infection, HBV-infected patients who also receive&#xD;
             antiviral treatment are not excluded.&#xD;
&#xD;
          -  Severe infection requires ICU treatment.&#xD;
&#xD;
          -  Serious complications such as hemophagocytic syndrome, DIC, etc.&#xD;
&#xD;
          -  Impairment of important organ functions: such as respiratory failure, chronic&#xD;
             congestive heart failure with NYHA grade ≥3, decompensated liver or kidney&#xD;
             dysfunction, hypertension and diabetes that cannot be controlled despite active&#xD;
             treatment.&#xD;
&#xD;
          -  Have a history of autoimmune diseases, have disease activity in the last 6 months, and&#xD;
             are still taking oral immunosuppressive therapy within the past three months, with a&#xD;
             daily dose of oral prednisone greater than 10 mg.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Those who are known to be allergic to drugs in the CAPA regimen.&#xD;
&#xD;
          -  Patients with other tumors who need surgery or chemotherapy within 6 months.&#xD;
&#xD;
          -  Other experimental drugs are being used.&#xD;
&#xD;
          -  The investigators believe that other clinical conditions (including medical history or&#xD;
             the presence of comorbidities) of the patient will significantly increase the risk of&#xD;
             the subject when using the study treatment drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rong Tao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiaotong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rong Tao, MD</last_name>
    <phone>008621-25077603</phone>
    <email>hkutao@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chuanxu Liu, MD</last_name>
    <phone>008621-25077607</phone>
    <email>liuchuanxu@xinhuamed.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiming Li, MD</last_name>
      <phone>0086-020-87343765</phone>
      <email>lizhm@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Zhiming Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Eye Ear Nose and Throat Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Ding, MD</last_name>
      <phone>+86-21-64377134</phone>
      <email>eentding@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Xinhua hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanxu Li, MD</last_name>
      <phone>008621-25077607</phone>
      <email>liuchuanxu@xinhuamed.com.cn</email>
    </contact>
    <investigator>
      <last_name>Rong Tao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Rong Tao</investigator_full_name>
    <investigator_title>Associate director of department of hematology</investigator_title>
  </responsible_party>
  <keyword>camrelizumab</keyword>
  <keyword>apatinib</keyword>
  <keyword>pegaspargase</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>natural killer/T-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

